Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma

Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma

Victor Jeannot,1,2 Benoit Busser,1–3 Laetitia Vanwonterghem,1,2 Sophie Michallet,1,2 Sana Ferroudj,1,2 Murat Cokol,4 Jean-Luc Coll,1,2 Mehmet Ozturk,1,2,5 Amandine Hurbin1,2 1INSERM U1209, Department Cancer Targets and Experimental Therapeutics, Grenoble, France; 2University Grenoble Alpes...

Full description

Bibliographic Details
Main Authors: Jeannot V, Busser B, Vanwonterghem L, Michallet S, Ferroudj S, Cokol M, Coll JL, Ozturk M, Hurbin A
Format: Article
Language:English
Published: Dove Medical Press 2016-11-01
Series:OncoTargets and Therapy
Subjects:
targeted therapy
combined treatments
non-small-cell lung cancer
hepatocarcinoma
Online Access:https://www.dovepress.com/synergistic-activity-of-vorinostat-combined-with-gefitinib-but-not-wit-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/synergistic-activity-of-vorinostat-combined-with-gefitinib-but-not-wit-peer-reviewed-article-OTT

Similar Items